

## **Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus (T2DM)**

*Han E, et al. Diabetes Metab Syndr Obes. 2020 Nov 2; 13:4113-4121.*

- In this study, total 164 T2DM patients were included who switched from linagliptin to teneligliptin for >12 weeks.
- Switching from linagliptin to teneligliptin improved fasting blood glucose ( $148.1 \pm 47.1$  to  $139.6 \pm 43.4$  mg/dL), glycated hemoglobin - HbA1c ( $7.9 \pm 1.3$  to  $7.5 \pm 1.2\%$ ), and postprandial blood glucose ( $224.8 \pm 77.4$  to  $205.8 \pm 70.8$  mg/dL) levels.
- Low-density lipoprotein cholesterol (LDL-C) concentration was reduced while liver and kidney functions were maintained.

**Switching from linagliptin to teneligliptin helps maintain kidney function and reduce blood glucose safely in older patients with T2DM.**